Accelerating Early Stage Biotech Startups in ASEAN

The ASEAN region is witnessing a paradigm shift in biotechnology, driven by a surge in academic research and a growing appetite for venture capital. Early-stage biotech startups in Southeast Asia are uniquely positioned to leverage local biodiversity and a diverse genetic pool to develop novel therapeutics and diagnostic tools. Our focus is on identifying founders who combine scientific rigor with scalable business models.

Novel Drug Discovery

Investing in early-stage platforms that utilize AI and high-throughput screening to identify new molecular entities.

Biomarker Development

Supporting startups creating precision diagnostic tools tailored to the genetic profiles of Southeast Asian populations.

Cell and Gene Therapy

Funding the next generation of regenerative medicine and targeted therapies for chronic diseases.

Agricultural Biotech

Exploring the intersection of pharma and agritech to create sustainable bio-based ingredients.

Strategic Support for Seed-Stage Ventures

Navigating the "valley of death" in biotech requires more than just capital. We provide our portfolio companies with a comprehensive ecosystem of mentorship, regulatory guidance, and strategic introductions. By analyzing Sector Analysis data, we help startups pivot their strategies to meet global market demands while maintaining regional relevance.

Access to specialized laboratory infrastructure and incubators.
Guidance on Intellectual Property (IP) filing and protection in multiple jurisdictions.
Connections to clinical trial networks across Singapore, Thailand, and Vietnam.
Strategic matchmaking with late-stage venture partners for Series A funding.

Our investment thesis prioritizes scientific validity and the potential for disruptive impact on public health across the ASEAN bloc.

To understand how we evaluate early-stage risks, we encourage investors to review our Market Ratings, which provide a benchmark for valuation and growth potential in the biotech sector.